Oxford Ledge
Search
DexCom, Inc. (NASDAQ: DXCM) is a $22.2B medical - devices company trading at $57.64 (−6.4% today) — 27.6× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 02:26 UTC.
This company manufactures medical devices, including continuous glucose monitoring systems, that are subject to FDA regulatory oversight. Before marketing devices, the company must obtain FDA authorization through processes like the 510(k) clearance pathway. After a device reaches the market, the company must comply with extensive requirements including facility registration, quality management systems, labeling restrictions, adverse event reporting to the FDA, and product recalls when necessary.
Summarized from DexCom, Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $57.64 |
| Change (1D) | -3.93 (-6.38%) |
| Market cap | $22.2B |
| 52-week range | $57.08 – $65.29 |
| Valuation | |
| P/E (TTM) | 27.58× |
| EV/EBITDA | 18.30× |
| EPS (TTM) | $2.09 |
| Price/book | 8.08× |
| Return on equity | 30.46% |
| Returns | |
| 52-week return | +1.0% |
This company manufactures medical devices, including continuous glucose monitoring systems, that are subject to FDA regulatory oversight.
DXCM trades at $57.64, 27.58× trailing earnings, 18.30× EV/EBITDA, as of 2026-07-15.
DexCom, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-28. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-07-15 02:26 UTC. This page is also available as JSON at /api/data?ticker=DXCM and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for DXCM and 3,500+ tickers.
Create a free account — keep DXCMGET /api/data?ticker=DXCM
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt